The Cryopyrin-Associated Periodic Syndromes drugs in development market research report provides comprehensive information on the therapeutics under development for Cryopyrin-Associated Periodic Syndromes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cryopyrin-Associated Periodic Syndromes. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cryopyrin-Associated Periodic Syndromes and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Cryopyrin-Associated Periodic Syndromes by ten companies/universities/institutes. The top development phase for Cryopyrin-Associated Periodic Syndromes is preclinical with five drugs in that stage. The Cryopyrin-Associated Periodic Syndromes pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Cryopyrin-Associated Periodic Syndromes pipeline products market are: F. Hoffmann-La Roche, Novartis and 9 Meters Biopharma.
The key targets in the Cryopyrin-Associated Periodic Syndromes pipeline products market include NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3), Scavenger Receptor Cysteine Rich Type 1 Protein M130 (Hemoglobin Scavenger Receptor or CD163), and Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B).
The key mechanisms of action in the Cryopyrin-Associated Periodic Syndromes pipeline product include NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3) Inhibitor with seven drugs in Phase II. The Cryopyrin-Associated Periodic Syndromes pipeline products include six routes of administration with the top ROA being Oral and five key molecule types in the Cryopyrin-Associated Periodic Syndromes pipeline products market including Small Molecule, and Synthetic Peptide.
Cryopyrin-Associated Periodic Syndromes overview
cryopyrin-associated periodic syndromes are a group of autoimmune diseases caused by a defect in the cryopyrin protein. Genetic mutations on the NLRP3 gene result in overproduction of interleukin 1 beta due to excessive inflammasome activation. This is generally seen in children and is a rare form. It includes Neonatal Onset Multisystem Inflammatory Disease (NOMID), Muckle-Wells Syndrome (MWS) and Familial Cold Autoinflammatory Syndrome (FCAS). Symptoms are variable based on the individual conditions. Cold, fatigue, painful or burning rash, fever, joint pains, headache, and nausea are common symptoms. Diagnosis is difficult but based on physical examination and complete blood count to find out the levels of inflammatory mediators, skin biopsy and other lab examinations done. Anti inflammatory drugs to treat inflammation and supportive care are management steps.
For a complete picture of Cryopyrin-Associated Periodic Syndromes’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
